Abstract

The global pharmaceutical industry topped US$ 856 billion in 2011. In Brazilian market the situation is also very favourable, bearing in mind that Brazil forms part of “pharmerging markets”. The economic expansion, new development policies and rise of new social classes are some factors that promote the nation’s economy. For the fine chemical and pharmaceutical manufacturing is no different Among the family of antibiotics, it is worth mentioning amoxicillin and ampicillin, has been a strong trend in consumer, with sales over 6 billion pharmaceutical units and US$ 46 million/year for active pharmaceutical ingredient. Therefore, the present article examines the trends and increasing of amoxicillin and ampicillin in Brazilian market with regard to the opportunities ahead.

BACKGROUND

The pharmaceutical global market should maintain an annual growth ranging from 4 to 7 percent, at least until 2015, when the brand will surpass US$1 trillion (1). According to the Brazilian Association of Pharmaceutical Chemicals and Raw Material (ABIQUIFI), the trade deficit in pharmaceutical chain is growing every year. In 2011, reached US$ 8,413 billion against US$ 4.8 billion in 2009, corresponding to more than 75 percent (2).
Amoxicillin is the antibiotic most commonly prescribed by doctors in the Health Unique System (SUS – Brazilian term) in Brazil, as well as in the private market for the treatment of various infections. The salts of antibiotics are among the top 10 Brazilian imported products (1, 2). The ampicillin is used as an alternative in the treatment of cystitis in pregnant women and also used in associations and / or less severe infections in the respiratory tract, urinary, biliary and enteric.
With the discovery of antibiotics in the mid-twentieth century, life expectancy increased an estimated 10 years in industrialized countries (4). After discovery of penicillin (5) and isolation of the acid 6-amino-penic ...